Key Updates
Moderna shares advanced 5.93% to $53.27 since the February 24th report, extending the remarkable YTD rally to 80.64%. The latest movement reflects continued momentum following the FDA's reversal on the flu vaccine application, though tempered by ongoing regulatory uncertainty and funding policy debates. Two significant developments emerged: the FDA Commissioner publicly defended mRNA vaccines while justifying the termination of over $700 million in federal funding, and BioNTech escalated patent litigation by filing a new lawsuit targeting Moderna's next-generation COVID vaccine mNEXSPIKE, which represents 55% of projected COVID vaccine revenue for the 2025-26 season. The stock has now gained 110.14% over six months, demonstrating sustained investor confidence despite mounting regulatory and legal headwinds.
Current Trend
Moderna exhibits exceptional bullish momentum with YTD gains of 80.64%, supported by strong performance across all timeframes: +5.44% (1d), +14.31% (5d), +11.00% (1m), and +110.14% (6m). The stock has decisively broken above the $50 resistance level that constrained price action in previous reports, establishing a new technical foundation at current levels. The six-month trajectory suggests a sustained recovery from pandemic-era lows, with the stock more than doubling from the $25-30 range. Recent price action shows consistent upward pressure despite negative news flow, indicating strong institutional accumulation. The current level of $53.27 represents a critical juncture, with the stock testing the upper bounds of its recent trading range and approaching the psychological $55 resistance level.
Investment Thesis
The investment thesis centers on Moderna's transition from a single-product COVID vaccine company to a diversified mRNA platform with multiple revenue streams by 2028. The company targets breakeven by 2028 through three approved products including the next-generation mNexspike COVID vaccine (24% U.S. retail market share), international expansion into the $1.8 billion European respiratory vaccines market, and strategic partnerships across Latin America and Asia Pacific. The thesis assumes successful regulatory approvals for the flu vaccine in international markets (EU, Canada, Australia) and eventual U.S. approval following the FDA's reversal decision, with potential availability for the 2026-27 flu season. Critical to this thesis is the company's ability to achieve 10% revenue growth in 2026 with 85% of revenue concentrated in the second half, while managing $3 billion in annual R&D spending against projected year-end cash of $5.5-6 billion. The international pivot becomes increasingly important as U.S. regulatory uncertainty intensifies and federal funding support evaporates.
Thesis Status
The investment thesis faces mounting execution risks despite recent stock performance. The FDA's acceptance of the modified flu vaccine application provides a pathway to approval by August 2026, supporting the diversification strategy, but the requirement for post-marketing studies in elderly populations and comparative trials against high-dose vaccines introduces commercialization delays and additional costs. The termination of over $700 million in federal funding and FDA Commissioner Makary's explicit statement that companies generating $50 billion from COVID vaccines should self-fund research fundamentally alters the capital allocation equation. The policy shift forces Moderna to absorb development costs previously subsidized by government, compressing margins and extending the breakeven timeline. The BioNTech patent lawsuit targeting mNEXSPIKE—projected to represent 55% of COVID vaccine revenue—introduces material revenue risk if successful, potentially forcing product modifications or royalty payments. The international expansion strategy gains credibility with partnerships in the U.K., Canada, and Australia, though the projected 50% international revenue mix in 2026 (versus 62% U.S. in 2025) represents a significant geographic rebalancing requiring flawless execution.
Key Drivers
The primary catalyst remains the FDA's flu vaccine review decision expected by August 2026, with approval enabling entry into the multi-billion dollar seasonal influenza market and validating the mRNA platform beyond COVID applications. The regulatory pathway now includes full approval for adults 50-64 and accelerated approval for those 65+, with mandatory post-marketing studies potentially delaying full commercialization until 2027-28. The BioNTech patent litigation represents a significant headwind, with the lawsuit alleging infringement of mRNA vaccine technology used in Comirnaty, potentially forcing costly settlements or product modifications that could impact 55% of COVID vaccine revenue. The termination of federal mRNA funding and Commissioner Makary's public stance that profitable companies should self-fund research eliminates a key competitive advantage and increases capital intensity for pipeline development. Q4 results demonstrated resilience with $678 million revenue exceeding estimates despite a 26% decline in U.S. COVID vaccine demand, while aggressive cost-cutting reduced R&D expenses by 31%, improving the path to profitability. International expansion gains traction with regulatory submissions in the EU, Canada, and Australia for the flu vaccine, positioning Moderna to capture the $1.8 billion European respiratory vaccines market and diversify geographic revenue concentration.
Technical Analysis
Moderna exhibits strong bullish momentum with the stock trading at $53.27, up 80.64% YTD and 110.14% over six months. The recent breakout above $50 resistance establishes a new technical foundation, with the stock forming higher lows at $45 (5-day support) and higher highs approaching $55. The 14.31% gain over five days and 11.00% monthly advance indicate accelerating upward momentum supported by increasing volume. The six-month chart reveals a sustained recovery from the $25 range, with the stock more than doubling and breaking through multiple resistance levels at $30, $40, and $50. Current price action suggests consolidation near $53 following the recent surge, with the psychological $55 level representing immediate resistance. Key support now resides at $50 (former resistance turned support) and $45 (20-day moving average area). The stock's ability to maintain gains despite negative news flow (patent litigation, funding cuts) demonstrates strong institutional demand and suggests further upside potential if the August FDA decision proves favorable. A break above $55 would target the $60-65 range, while failure to hold $50 support could trigger profit-taking back toward $45.
Bull Case
- FDA reversal provides clear regulatory pathway with August 2026 decision timeline: The agency's acceptance of Moderna's modified flu vaccine application after initial rejection creates a defined approval pathway, with full approval sought for adults 50-64 and accelerated approval for 65+, potentially enabling market entry for the 2026-27 flu season. Source: WSJ
- International expansion strategy gains momentum with regulatory submissions in multiple major markets: Moderna's flu vaccine applications remain under review in the EU, Canada, and Australia, with approvals expected later this year, positioning the company to capture the $1.8 billion European respiratory vaccines market and diversify beyond U.S. dependence. Source: Reuters
- Q4 revenue beat demonstrates resilient COVID vaccine demand with less severe decline than anticipated: Fourth-quarter sales of $678 million exceeded Wall Street estimates of $625 million, with U.S. COVID vaccine demand declining only 26% versus the anticipated 40% drop, while the next-generation mNexspike captured 24% U.S. retail market share. Source: Bloomberg
- Aggressive cost-cutting improves path to 2028 breakeven target with 31% R&D expense reduction: Moderna narrowed its quarterly loss to $2.11 per share from $2.91 per share year-over-year while cutting R&D expenses by 31%, maintaining its 10% revenue growth target for 2026 with 85% of revenue expected in the second half. Source: Bloomberg
- Clinical superiority demonstrated with flu vaccine showing 27% greater efficacy than GSK comparator: The mRNA-based flu vaccine mRNA-1010 demonstrated 26.6-27% greater efficacy than approved seasonal flu shots from GSK in clinical trials, with no safety concerns identified, supporting premium pricing potential upon approval. Source: Forbes
Bear Case
- BioNTech patent lawsuit threatens 55% of COVID vaccine revenue with mNEXSPIKE infringement claims: BioNTech filed suit alleging Moderna's next-generation COVID vaccine mNEXSPIKE violates patents related to mRNA vaccine technology, with the product projected to represent 55% of Moderna's COVID vaccine revenue during the 2025-26 respiratory season, potentially forcing costly settlements or product modifications. Source: Reuters
- Federal funding termination eliminates $700 million in government support and increases capital intensity: The U.S. Department of Health and Human Services terminated over $700 million in funding to Moderna for mRNA vaccine development, with FDA Commissioner Makary stating that companies generating $50 billion from COVID vaccines should self-fund research, fundamentally altering the capital allocation equation. Source: Reuters
- Regulatory uncertainty intensifies with FDA leadership changes and heightened scrutiny of mRNA technology: The FDA's initial rejection of the flu vaccine application followed by reversal demonstrates inconsistent regulatory standards under new leadership including vaccine chief Dr. Vinay Prasad, who has publicly criticized mRNA vaccines, creating unpredictable approval pathways for future products. Source: WSJ
- Revenue concentration risk with 85% of 2026 revenue projected in second half creates execution vulnerability: Moderna expects 85% of 2026 revenue to materialize in the second half of the year, creating significant quarterly volatility and execution risk if respiratory season demand disappoints or regulatory approvals face delays. Source: WSJ
- Cash burn continues with $3 billion annual R&D spending against declining COVID revenue base: Moderna plans to spend approximately $3 billion on R&D in 2025 while projecting year-end cash between $5.5-6 billion, with the company still posting quarterly losses of $826 million despite cost-cutting, raising concerns about capital adequacy if pipeline products face delays. Source: WSJ